Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Korean Post-Marketing Surveillance Study On Erbitux (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck (originally EMR 62241-508) and in Patients With EGFR-expressing, KRAS wild-type Metastatic Colorectal Cancer (originally EMR 62202-509)

Next Previous
Trial Profile

A Korean Post-Marketing Surveillance Study On Erbitux (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck (originally EMR 62241-508) and in Patients With EGFR-expressing, KRAS wild-type Metastatic Colorectal Cancer (originally EMR 62202-509)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Antineoplastics
  • Indications Colorectal cancer; Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Registrational
  • Sponsors Merck KGaA

Most Recent Events

  • 28 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov records (NCT01075828 and NCT01082315).
  • 28 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov records (NCT01075828 and NCT01082315).
  • 01 Mar 2013 Planned end date changed from 1 Jul 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov record (NCT01075828).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top